VIRAMUNE 400 mg, extended-release tablet 30 tablets
Active ingredients: Nevirapine
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VIRAMUNE 400 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- BOEHRINGER INGELHEIM INTERNATIONAL
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69410368CIP72189898CIP133400921898989Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| NÉVIRAPINE ANHYDREcomprimé | 400 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.